Hair Loss Issues
GSK is believed to have entered Phase III trials with Dutasteride for hair loss. Their Supplemental New Drug Application for hair loss is thought to have been submitted to the FDA sometime in 2001. Avodart™ appears to have a much greater and longer inhibition of DHT than Propecia (Finasteride) in the early testing phases. Is it better than Propecia, and are its side effects greater or more serious? These are questions that are unanswered at this time – but time will tell. It's currently approved in a 0.5 mg softgel form.
Dutasteride, a second-generation 5 alpha-reductase inhibitor, is the first and only medicine to inhibit both the type 1 and type 2 enzymes responsible for the conversion of testosterone to DHT (dihydrotestosterone), the primary cause of prostate growth. Dutasteride's dual inhibition has been found to decrease levels of DHT by 90 percent at two weeks and 93 percent at two years.
Dutasteride Phase 2 Hair Counts
After six month of treatment, the hair counts measured in a 1 inch diameter circle increased by about ~96 hairs with 0.5mg Dutasteride, compared to about ~72 hairs with 5mg Finasteride.